ID
13564
Beschreibung
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00081822
Link
https://clinicaltrials.gov/show/NCT00081822
Stichworte
Versionen (1)
- 16.02.16 16.02.16 -
Rechteinhaber
CC BY-NC 3.0
Hochgeladen am
16. Februar 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Acute Myeloid Leukemia NCT00081822
Eligibility Acute Myeloid Leukemia NCT00081822
- StudyEvent: Eligibility
Beschreibung
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschreibung
patients with pre-existing myelodysplastic syndrome, or with antecedent hematologic disorder of >3 months duration, will be excluded. those with concomitant myelodysplasia/trilineage dysplasia noted at the time of diagnosis of aml will be eligible 74
Datentyp
boolean
Alias
- UMLS CUI [1]
- C3463824
- UMLS CUI [2]
- C0018939
Beschreibung
have secondary aml (aml following chemotherapy or radiation therapy).
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0280449
Beschreibung
have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0009488
Beschreibung
have a psychiatric disorder(s) that would interfere with consent, study participation or follow-up.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021430
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Beschreibung
are receiving other chemotherapy or corticosteroids (unless the latter is administered at a low dose for pre-medication purposes or for the treatment of chronic conditions - e.g., rheumatoid arthritis).
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0392920
- UMLS CUI [2]
- C0001617
Beschreibung
have received prior treatment for leukemia. patients who have received growth factors, cytokine support, leukapheresis, hydroxyurea, or cranial irradiation will be allowed but must discontinue treatment at least 24 hours prior to beginning treatment with clofarabine. if used, hydroxyurea must be discontinued 48 hours prior to the initiation of chemotherapy.
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1514463
- UMLS CUI [2]
- C0018284
- UMLS CUI [3]
- C0199974
- UMLS CUI [4]
- C0023416
- UMLS CUI [5]
- C0020402
- UMLS CUI [6]
- C0079172
Beschreibung
have any other severe concurrent disease (severe coronary artery disease (nyha class >ii), significant neurological disorder, uncontrolled diabetes, etc.), which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1321605
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Beschreibung
have active central nervous system involvement with leukemia.
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1332884
Beschreibung
other malignancy within the past year, with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0006826
Ähnliche Modelle
Eligibility Acute Myeloid Leukemia NCT00081822
- StudyEvent: Eligibility
C0023487 (UMLS CUI [2])
C3688712 (UMLS CUI [3])
C1515708 (UMLS CUI [4])
C2825131 (UMLS CUI [5])
C0032961 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0018939 (UMLS CUI [2])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0001617 (UMLS CUI [2])
C0018284 (UMLS CUI [2])
C0199974 (UMLS CUI [3])
C0023416 (UMLS CUI [4])
C0020402 (UMLS CUI [5])
C0079172 (UMLS CUI [6])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])